• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·1795.TW
Share

Lotus Pharmaceutical Co., Ltd. Stocks

NT$ 191.5Last Updated 24.06.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

NT$ 1.60B

NT$ 191.5
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Lotus Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, specializing in the research, development, production, and sale of generic medicines. Its market presence extends across Taiwan, South Korea, the United States, and other global territories. The company primarily targets therapeutic areas such as oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system conditions with its generic product line. In addition to prescription generics, Lotus also offers a diverse array of over-the-counter drugs. Diversifying its business activities, the firm engages in the wholesale distribution of cosmetics, the retail of specialized clinical equipment, and provides biotechnology consulting. It also handles the sale of pharmaceuticals and medicinal chemicals, conducts marketing campaigns, offers market planning and business intelligence services, and provides advisory on health management and health technology. Furthermore, Lotus delivers a suite of services including project management for pharmaceutical regulatory compliance, data collection, and agency functions. It also operates as a healthcare consultancy and a Contract Research Organization (CRO). Established in 1966, Lotus Pharmaceutical Co., Ltd. maintains its principal office in Taipei City, Taiwan. The company is a subsidiary of Alvogen Emerging Markets Holdings Limited.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 1795.TW is 368 and suggests 92.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 13:03

Elon Musk Is No Longer a Trillionaire — Bloomberg

24.06.2026 11:37

Mag7 shares have experienced their biggest sell-off in over a year. What's next?

24.06.2026 10:35

Top Stories This Morning: Asia Recovers After Sell-Off, SpaceX Raises $25 Billion

24.06.2026 09:00

Apollo and Morgan Stanley have once again restricted withdrawals from private credit funds

24.06.2026 08:00

Alibaba has filed a lawsuit against the Pentagon over allegations of ties to the Chinese military

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026